CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC HUMAN

All Clinical Trials for secretin synthetic human

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036231 ↗	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction	Terminated	Repligen Corporation	Phase 3	2002-04-01	The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 ↗	Synthetic Human Secretin in Children With Autism	Completed	Repligen Corporation	Phase 3	2002-04-01	The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	National Institute on Deafness and Other Communication Disorders (NIDCD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00216294 ↗	Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder	Completed	Repligen Corporation	Phase 2	2005-02-01	The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
NCT00216294 ↗	Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder	Completed	Shekhar, Anantha M.D., Ph.D.	Phase 2	2005-02-01	The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.

Clinical Trial Conditions for secretin synthetic human

Condition Name

Condition Name for secretin synthetic human
Intervention	Trials
Autism	3
Chronic Pancreatitis	2
Intraductal Papillary Mucinous Neoplasms	1
Obsessive Compulsive Disorder (OCD)	1

Condition MeSH

Condition MeSH for secretin synthetic human
Intervention	Trials
Pancreatitis	4
Autistic Disorder	3
Pancreatitis, Chronic	2
Obsessive-Compulsive Disorder	1

Clinical Trial Locations for secretin synthetic human

Trials by Country

Trials by Country for secretin synthetic human
Location	Trials
United States	21

Trials by US State

Trials by US State for secretin synthetic human
Location	Trials
Massachusetts	4
Washington	2
Indiana	2
Colorado	2
Missouri	1

Clinical Trial Progress for secretin synthetic human

Clinical Trial Phase

Clinical Trial Phase for secretin synthetic human
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	2
Phase 1	3

Clinical Trial Status

Clinical Trial Status for secretin synthetic human
Clinical Trial Phase	Trials
Completed	5
Terminated	4
Unknown status	1

Clinical Trial Sponsors for secretin synthetic human

Sponsor Name

Sponsor Name for secretin synthetic human
Sponsor	Trials
Repligen Corporation	4
Massachusetts General Hospital	3
ChiRhoClin, Inc.	2

Sponsor Type

Sponsor Type for secretin synthetic human
Sponsor	Trials
Industry	6
Other	6
NIH	2